We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Parkinson’s Disease Patients at Higher Risk for Melanoma

By LabMedica International staff writers
Posted on 24 Jul 2017
Study finds that people with Parkinson’s disease have a much higher risk of the skin cancer melanoma, and vice versa. More...
Physicians treating patients with one disease should be vigilant for signs of the other in order to achieve early diagnosis and treatment, and patients should be educated about the risk of developing the other illness.

Medical experts have speculated about causes underlying the connection between Parkinson’s and melanoma for decades, with varying conclusions. Several studies have suggested levodopa, a drug for Parkinson’s, may be implicated in malignant melanoma, but others have found an association between the two diseases regardless of levodopa treatment.

According to a Mayo Clinic (Rochester, MN, USA) study led by Jose Pulido, MD: patients with Parkinson’s were roughly 4 times likelier to have had a history of melanoma than those without Parkinson’s, and patients with melanoma had a 4-fold higher risk of developing Parkinson’s. The study team used the Rochester Epidemiology Project medical records database to identify all neurologist-confirmed Parkinson’s cases from January 1976 through December 2013 among Olmsted County (MN, USA) residents. They examined the prevalence of melanoma in those 974 patients compared with 2,922 residents without Parkinson’s. They also identified 1,544 cases of melanoma over that period and determined the 35-year risk of Parkinson’s in those patients compared with the risk in people without melanoma.

The results support an association between Parkinson’s disease and melanoma, but argue against levodopa as the cause. It is likelier that common abnormalities underlie both conditions in patients who have both, but more research is needed to confirm that and refine screening recommendations.

“Future research should focus on identifying common genes, immune responses, and environmental exposures that may link these two diseases,” said first author Lauren Dalvin, MD, a Mayo Foundation scholar, “If we can pinpoint the cause of the association between Parkinson’s disease and melanoma, we will be better able to counsel patients and families about their risk of developing one disease in the setting of the other."

The study, by Dalvin LA et al, was published July 2017 in the journal Mayo Clinic Proceedings.

Related Links:
Mayo Clinic


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The US FDA has cleared TruVerus, the first multimodal benchtop blood analyzer for rapid, decentralized testing (Photo courtesy of Truvian Health)

Benchtop Analyzer Runs Chemistries, Immunoassays and Hematology in Single Device

Routine blood tests remain dependent on off-site laboratories, resulting in delays, higher costs, and logistical barriers in decentralized care settings. Now, a new multimodal diagnostic solution delivers... Read more

Hematology

view channel
Image: Research has linked platelet aggregation in midlife blood samples to early brain markers of Alzheimer’s (Photo courtesy of Shutterstock)

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more

Microbiology

view channel
Image: The SMART-ID Assay delivers broad pathogen detection without the need for culture (Photo courtesy of Scanogen)

Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples

Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.